Member Info for B2HS2L

troublesome, -
I think that the Instrument would have to be reprogrammed to make a difference to the processing time.
In the absence of this knowledge we must assume processing times remain unchanged.

Wilson, - I think that means we are waiting for an EUA then, - hopefully not long.

Hi Poidster -
Could I make a request please as you are well connected within q16/q32 users in NHS.

Could you advise if you hear of new instruments arriving in present or new locations, as that may indicate that GM has sanctioned further instruments to be made available to DHSC.
That was only supposed to happen when phase 2 was triggered, but it may be that things have moved on, and the content of phase 1 extension and phase 2 has become even less well defined, now that new SNPsig products
(suitable for q16/32 use ) have been launched.

It would be great to get information concerning which instruments are being used in Mobile testing units (MTUs), which are being utilised chasing down the SA virus mutation.

https://atamis-1928.cloudforce.com/sfc/p/#0O000000rwim/a/4J000000kEFW/0a.XEpAnsXhWLPDFwBk_JAjjG7TOqEVnG58sfxOiFmw

For the avoidance of doubt concerning contract publicity:

Contract for supply of goods and services 28 September 2020.

Clause 34 of schedule 2.

34 Publicity

34.1 The Supplier shall not and shall procure that its Sub-contractors shall not:

34.1.1 make any press announcements or publicise the contract in any way; or
34.1.2 use the authorities name or brand in any promotion or marketing or announcement, without the prior written consent of the authority.

34.2 The Authority shall be entitled to publicise the Contract in accordance with any legal obligation upon the Authority, including any examination of the contract, by the National Audit Office pursuant to the National Audit Act 1983 or otherwise.

34.3 The Provision of this Clause 34 (Publicity) shall apply during the Term and indefinitely after its expiry or the earlier termination of the contract.

Hope you haven't sold all your ncyt shares BJW.

Milcait -
Of note, the first three SNPsig® assays are also being deployed to an international consortium of leading academic and public health laboratories in the UK, Europe, US and Latin America7, assembled by Novacyt to support a global variant diagnostic surveillance study.

From the way it is written above, I believe that those entities assembled by Novacyt are working to support a global variant diagnostic surveillance study that already exists, - I may have the wrong end of the stick though.
Just my 2c

++++

These new products are the type of leading edge Innovation that large pharma find irresistible, and it won't be long before they start asking themselves 'Can we really sit and watch while another large pharma buys this company out, who are taking market share'?

In the same way, GM would have known that his plans to sell more test kits, would be disadvantaged by not owning the instrument manufacturer on which the tests could be used outside of a lab.
He realised that if someone else purchased IT-IS, - with products ideally placed for Near Patient Testing, NCYT would be permanently adversely affected, as his orders would be subject to the new owners priorities .

neilrich,

'All of the swabs confirmed to have Covid will be sent to labs for further testing'

could believe hey meant 'All of the swabs confirmed to have Covid will be sent to labs for further analysis'.

If this were the case, it still might be NCYT.

hamster -

NeilRich posted this at 17:12 last night:

https://atamis-1928.cloudforce.com/sfc/p/#0O000000rwim/a/4J000000kEFW/0a.XEpAnsXhWLPDFwBk_JAjjG7TOqEVnG58sfxOiFmw

Read the contract, Novacyt are not allowed to talk or publicise the DHSC contract and the supply of goods and services....it is as simple as that, hence the reason why we've not heard anything. Clause 34 of schedule 2.

NCYT is not hiding anything, from what we can gather Q32/Q16 rollout continues despite some initial issues and now DHSC are receiving PROMATE too.

Not sure Wilson, - The question I have is what type of a FDA authorisation is needed for these products.

Mayflower Bioscience has not sold Primerdesign products previously I believe, - they aren't a supplier in the spreadsheet.

Hi TimV

https://afsbio.com/search?q=SNPsig

If these are the three SNPsig choices you are referring to, they are SNPsig products, but not the products launched today :)

From RNS - "The first three SNPsig® assays, launched today, enable the identification of the non-variant virus and the UK, South Africa or Brazil variants, as well as any variant carrying the N501Y mutation."

Morning Wilson -

you posted this just now -

Pricing. Great spot by teg on twitter

https://twitter.com/GoundoulEl/status/1356500052651487232

Just tried to access SNPsig Real Time PCR Genotyping kit

Can't find this product on the Mayflower Bioscience website now.

Kaeren / Airline boy
'they are out knocking on the doors of all passengers who have flown in from S.A '

Have we heard the Govnt talk about 'surge testing' in the recent past or was it invented today?
They are using Mobile testing units (MTUs), so they are definitely anxious.

https://www.gov.uk/government/news/surge-testing-to-be-deployed-to-monitor-and-suppress-spread-of-covid-19-variant

I think they fear the SA virus meeting up with other viruses to spawn other varients, which vaccines may or may not be able to handle.

Gazman123 -

https://www.genomeweb.com/business-news/thermo-fisher-scientific-acquire-mesa-biotech-550m?utm_source=Sailthru&utm_medium=email&utm_campaign=GW%20MDx%20Thurs%202021-01-21&utm_term=Molecular%20Diagnostics%20Bulletin#.YAqteNj7RhF

Nothing we don't know already in this article except:

...."Two weeks ago, the FDA issued an alert to clinical labs and healthcare providers, saying that Mesa's SARS-CoV-2 test, along with coronavirus tests from Thermo Fisher and Applied DNA Sciences, may yield false-positive results if certain mutations are present in the viral genome."

+++

I previously posted this on this BB

Loving the effort going into identifying positives in the area.
Lets hope we get results instead of just causing concern :)

Rumandpoker

If there was a vote down button I'd be using it on your posts today.
Suggest you use the following to realise this is a buying opportunity for those switched on enough to realise, and patient enough to await an sp reversal.

Use the following research to verify:

https://www.dropbox.com/sh/jtgl2ffh6lv34ww/AABCsFP3cATopsJTbhJEwOc4a?dl=0

particularly "00) Novacyt Financial Analysis as at 30th January 2021.pdf"

Please reassure Long Term Holders we have not accumulated this much knowledge for free dissemination to future investors for it to be ignored by posters posting piffle like yours..

Milcait,

From 29.09.2020 RNS:
"Under the terms of the contract, which is in two phases, Primerdesign will supply its products to the DHSC for up to six months. Phase one has an initial fixed term of 14 weeks with the potential to extend supply by a further 10 weeks. This first phase of the contract will involve the immediate deployment of 300 PCR instruments, related kits and support services with a minimum value of £150 million for the first 14 weeks. Based on this initial period, a further £100 million of revenue could be expected for the subsequent 10 weeks, however volumes can be varied up or down subject to certain notice criteria given by the DHSC.

The second phase of the contract, which is optional by the DHSC, allows for the provision of up to 700 additional PCR instruments, related kits and support services, as well as additional COVID-19 products from the Company's portfolio where required. "

+++
Phase 2 stated 'as well as additional COVID-19 products from the Company's portfolio where required' but not phase 1.

I'm sure GM would have offered new products from the Company's portfolio (PROmate), if assists to gets phase 2 signed.

JM2c

PROP5,

Was writing the below on notepad, and came back to find you suggested something similar.
Here's what I wrote:

Many on this BB are concerned about inadequate PR and forward statement from the company.

Perhaps you should all send the same pre-agreed message,
signed 'member of LSE NCYT Bulletin Board and concerned NCYT shareholder' - to GM AND DIRECTORS at the same time.

It will help to take the heat out of the sp taking a beating yesterday, when some feel inadequate PR was partly to blame.

I shan't be doing so because I feel that taking the company from an sp of <£1 to £9 in one year, says to me GM and Co must be doing something right.
If he wants to say little, his position is fine with me, but I don't think you guys should spend the weekend (& beyond) discussing this without taking action.
Sending the same message (perhaps at the exact same time on Monday), may cause it's clear concise content to be discussed at board level.
If done soon, it will not be too late for GM to ask the brokers to insert a quote expounding on PR and a new forward statement in their imminent broker notes.
From the foregoing, it seems that this is the sort of feedback you feel GM and directors should be receiving - no?

tkr, - PR we have here useless.imho.

The PR that could be generated by the use of the
Daily bioinformatic analysis of the Primerdesign Coronavirus COVID-19, - the specificity statement

https://www.genesig.com/assets/files/COVID_19_Specificity_Statement_issue_49.pdf

is a real asset to us.

The only Assay manufacturer who bothers to QUICKLY check the assay they make still detects all different virus strains.
What is this worth to reassure all purchasers of the assay validity.
I'm sure the Bioinformatics team and its regular reports have ensured the sale of Novacyt assays, in fierce competition from other assay manufacturers, - when public health authorities decide which assay they will purchase.
So why not shout it from the rooftops.
HEY - The recently discovered Brazil / South Africa / Timbuktoo strain. - We can detect them all.
Place that on social media, not some of the strange output we have recently seen.

try2buylow -
Just my 2 cents, but I have always thought that at the end of September, when ph1 /2 were announced, IT-IS was not owned by NCYT, although it is likely an acceptable offer had been made.
Thus Graham may well have said that only 300 q16 / q32 units were likely to be available short term, and that was the constraint that shaped the deal, ie 300 ph1, possible 700 ph2.

PRB769,

You also have to factor in the cost of Chartwell Consultants, who IMO have done a terrific job.

I have been invested long enough to remember the sp shenanigans last Feb / March.
I'm ignoring what's going on now, because I have no funds with which to top up.
However I am concentrating on GM's preparations for the future:

GM - at the end of the Novacyt Group AGM - 29.09.2020 -
"We are at the beginning not at the end of this transformative change".

Since then we have:

1 Strategic purchase IT-IS International.

2 Hired John McCarthy

GM - "On behalf of the Board, I am pleased to welcome James to the role of CFO. He joins Novacyt having held senior finance positions at a number of large blue-chip manufacturing organisations. His considerable financial, commercial and Board experience will be invaluable as Novacyt embarks on its next stage of growth."

3 Hired Guillermo Raimondo

4 Appointed Anthony Dyer Chief Corporate Development Officer

GM - "Anthony's new, important role reflects the Company's growth strategy, which includes selective potential M&A to supplement organic growth initiatives.
I look forward to working with Anthony and James as part of an expanded executive team."

H2 2020 EBITDA above £143 million, = £785,000 / day = current rate of Earnings before Interest, Tax, Depreciation & Amortisation

Starting to look, smell, feel and taste like a Mid-Cap. - The sort of competition big pharma will begin to put on their radar because it is:

1 taking market share

2 innovative

3 Hired many people and placing big hitters in senior roles

4 Is inside DHSC and develops what their customer wants quickly.

5 Publically stated it intends to be acquisitive

6 Has no Debt.

7 Has banked 100 Mil Euros at end of 2020.
Since 01.01.2021, @ £785,000 / day = current rate of Earnings before Interest, Tax, Depreciation & Amortisation,
Has accumulated another 29 * £785,000 = £22.76 Million in January.